Marinus Pharmaceuticals Comments On Ovid Therapeutics' Patent Challenge And Provides Update On Marinus' Post Grant Review
Portfolio Pulse from Benzinga Newsdesk
Marinus Pharmaceuticals is defending its patent for ganaxolone in treating status epilepticus against a challenge by Ovid Therapeutics. The challenge, filed on March 26, 2024, targets U.S. Patent 11,110,100. Marinus holds multiple patents for ganaxolone's use in SE and RSE treatment.
March 27, 2024 | 12:43 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Marinus Pharmaceuticals is actively defending its patent for ganaxolone, a treatment for status epilepticus, against a challenge from Ovid Therapeutics.
The outcome of the patent challenge could impact Marinus Pharmaceuticals' exclusive rights to ganaxolone for SE and RSE treatment, potentially affecting its market position and future revenues. However, the presence of multiple patents for ganaxolone and the ongoing legal process make the short-term impact on the stock price uncertain.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90